Valuation

GSKGSK plc

StockLSEUnited KingdomHealth careEU retail: available

−4.8% today · +11.4% over a year

10/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 86% of the instruments we score

Priced lower than most peers. Dividend yield 3.71%.

GSK plc (GSK) valuation against sector peers: P/E 13.8 (sector median 22.4), P/B 4.8, EV/EBIT 11.3, free-cash-flow yield 8.1%, P/S 2.4.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricGSKSector medianvs median
P/E13.822.4 · n=2838% below
P/B4.83.6 · n=4536% above
P/S2.44.5 · n=4046% below
EV/EBIT11.320.8 · n=2846% below
Free-cash-flow yield8.1%3.5% · n=41134% above
Dividend yield3.71%0.12% · n=1003,007% above
Return on equity38.0%6.8% · n=56463% above
Return on invested capital26.8%7.0% · n=47281% above
Gross margin72.4%70.2% · n=39near the median
Net debt / EBITDA1.081.39 · n=2622% below

Value factor: 88 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NVSNovartis AG21.36.517.95.9%2.5%9/10
NOVNNovartis AG21.26.417.85.9%2.9%10/10
AZNAstraZeneca plc25.75.420.94.5%1.9%6/10
AZNAstraZeneca PLC25.75.420.94.5%1.3%6/10
NVONovo Nordisk A/S11.25.99.85.2%4.8%7/10
SNYSanofi11.81.316.37.8%5.0%7/10
SANSanofi SA11.81.316.27.8%5.5%8/10
TEVATeva Pharmaceutical Industries Limited66.06.037.22.9%0.0%6/10
ALCAlcon34.71.527.35.1%0.4%4/10
ALCAlcon AG34.51.527.25.1%0.5%6/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 06 Mar 2026